Bimekizumab Effective for Patients With Moderate to Severe HS

Data from two phase 3 studies "support the use of bimekizumab as a promising new therapeutic option for patients with moderate to severe hidradenitis suppurativa," the authors concluded.
Medscape Medical News

source https://www.medscape.com/viewarticle/phase-3-trials-bimekizumab-effective-moderate-severe-2024a1000alz?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?